Blood Research Theme

The Blood Theme is working to develop a robust, end-to-end pipeline for gene editing therapies. 

The initial focus is on primary immune deficiencies associated with Epstein-Barr virus (EBV).

Our initial work explores ex vivo base editing applications: blood can be taken from patients, treated with our therapy in a laboratory, and tested before being transfused back into the patient.

This work is designed to de-risk the complex regulatory and manufacturing pathways for all future MRC CoRE gene editing therapies: creating a comprehensive template for engagement with bodies like the MHRA and FDA, patient involvement, and clinical readiness that can be applied to a wider range of blood and immune disorders in the future. The Blood Theme will also develop a Genomic Multi-disciplinary Team (MDT) to decide on candidate target genes, and source patients and clinical data, as well as a Process Development MDT to align critical methodologies.

Research projects

Theme publications

Team

Related resources